Jeffrey E. Gershenwald
Impact in
- Oncology top 0.02%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Dermatology top 0.05%
- Cutaneous lymphoproliferative disorders research
Papers in
- Oncology 232
- Cutaneous Melanoma Detection and Management 177
- CAR-T cell therapy research 39
- Cancer Immunotherapy and Biomarkers 27
-
- Melanoma and MAPK Pathways 69
- Co-authors
- Merrick I. Ross (129 shared papers)Charles M. Balch (22 shared papers)John F. Thompson (27 shared papers)John M. Kirkwood (18 shared papers)Kelly M. McMasters (21 shared papers)Daniel G. Coit (14 shared papers)Jeffrey E. Lee (60 shared papers)Michael B. Atkins (12 shared papers)
- Journals
- Journal of Clinical Oncology (49 papers)Annals of Surgical Oncology (32 papers)Cancer (18 papers)Clinical Cancer Research (11 papers)Cancer Research (10 papers)
- Partner nations
- United StatesAustraliaItaly
In The Last Decade
Jeffrey E. Gershenwald
277 papers receiving 24.9k citations
Jeffrey E. Gershenwald's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 19.6k
- Dermatology 3.1k
- Immunology and Allergy 1.8k
- Biophysics 1.4k
- Immunology 5.0k
Countries citing papers authored by Jeffrey E. Gershenwald
This map shows the geographic impact of Jeffrey E. Gershenwald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey E. Gershenwald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey E. Gershenwald more than expected).
Fields of papers citing papers by Jeffrey E. Gershenwald
This network shows the impact of papers produced by Jeffrey E. Gershenwald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey E. Gershenwald. The network helps show where Jeffrey E. Gershenwald may publish in the future.
Co-authors
The 25 scholars most cited alongside Jeffrey E. Gershenwald, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 283 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Final Version of 2009 AJCC Melanoma Staging and Classification Hit paper breakdown → | 2009 | 3342 |
| 2 | Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma Hit paper breakdown → | 2001 | 1995 |
| 3 | Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System Hit paper breakdown → | 2001 | 1776 |
| 4 | Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual Hit paper breakdown → | 2017 | 1437 |
| 5 | Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients Hit paper breakdown → | 1999 | 865 |
| 6 | NRAS mutation status is an independent prognostic factor in metastatic melanoma Hit paper breakdown → | 2011 | 528 |
| 7 | Melanoma Hit paper breakdown → | 2015 | 441 |
| 8 | 1998 | 434 | |
| 9 | Guidelines of care for the management of primary cutaneous melanoma Hit paper breakdown → | 2018 | 393 |
| 10 | Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system Hit paper breakdown → | 2010 | 383 |
| 11 | Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. | 1997 | 359 |
| 12 | Cutaneous melanoma Hit paper breakdown → | 2023 | 350 |
| 13 | 2011 | 347 | |
| 14 | The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care Hit paper breakdown → | 2018 | 336 |
| 15 | 2000 | 325 | |
| 16 | 2006 | 312 | |
| 17 | 2004 | 303 | |
| 18 | 2010 | 287 | |
| 19 | 2006 | 279 | |
| 20 | 2011 | 250 |
About Jeffrey E. Gershenwald
Jeffrey E. Gershenwald is a scholar working on Oncology, Molecular Biology, Epidemiology, Immunology and Dermatology, having authored 283 papers that have together received 25.5k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (177 papers), Melanoma and MAPK Pathways (69 papers), Nonmelanoma Skin Cancer Studies (50 papers), Immunotherapy and Immune Responses (41 papers), CAR-T cell therapy research (39 papers), Cancer Immunotherapy and Biomarkers (27 papers), Cell Image Analysis Techniques (24 papers) and Cutaneous lymphoproliferative disorders research (18 papers). The work is most often cited by research in Oncology (19.6k citations), Dermatology (3.1k citations), Immunology and Allergy (1.8k citations), Biophysics (1.4k citations) and Immunology (5.0k citations). Jeffrey E. Gershenwald has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Merrick I. Ross, Charles M. Balch, John F. Thompson, John M. Kirkwood, Kelly M. McMasters, Daniel G. Coit, Jeffrey E. Lee, Michael B. Atkins, Paul F. Mansfield and Arthur J. Sober. Their work appears in journals such as Journal of Clinical Oncology, Annals of Surgical Oncology, Cancer, Clinical Cancer Research and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.